Theralpha a biopharmaceutical company supported by Paca-Est Incubator at Sophia Antipolis and specialized in the development of new pain-relief therapies, has announced the launch of SubAlgic, a three-year preclinical and clinical development program for a new high-potential analgesic, THA903.
The SubAlgic consortium includes Synprosis, a company based in Aix-en-Provence, supported by Incubator Impulse and specialist in peptide synthesis, formulation and optimization, the Institute of Molecular and Cellular Pharmacology (IPMC, Sophia Antipolis), a world-renowned center in neurosciences, and the Clermont Ferrand Center of Clinical Investigation, a European leader in pain clinical trials. The SubAlgic program is accredited by the Eurobiomed cluster as part of the 12th FUI (Fond Unique Interministeriel) and supported by the Conseil Général des Alpes maritimes, the PACA Region, the Communauté du Pays d'Aix en Provence and the Clermont Communauté, with financing totalling €2.55M.
The SubAlgic program aims to develop a new drug (THA903) which does not interact with opioid receptors and which can be administered sublingually. It should aid acute pain management. THA903 is a small peptide composed of eleven natural amino acids. It is derived from a toxin present in king cobra venom. This peptide has already shown promising efficacy and tolerability in preclinical animal models through sublingual delivery. The SubAlgic program includes preclinical development completion and a first clinical study in humans.
''We are extremely proud of obtaining this major grant as part of the 12th FUI, allowing the development of our drug candidate THA903, with the collaborative support of key experts. So many pain patients are in need of new treatment options,” comments David Dellamonica, CEO of Theralpha.
“The SubAlgic program, through the development of THA903, should allow the development of a powerful new therapeutic class. Moreover, THA903 is not an opiate derivative, whose problems of tolerance and side effects, such as respiratory depression and opioid-induced bowel dysfunction, are well known. We will customize a specific model for THA903 (translational multiarray) to highlight the pharmacodynamic potential in the earliest Phase I studies of this new drug,” comments Professor Claude Dubray, MD, PhD, Director of the CIC in Clermont Ferrand.